Bone Health

Immunology

Hematology

Respiratory

Dermatology

Diabetes

Gastroenterology

Neurology

Oncology

Ophthalmology

Rare Disease

Rheumatology

News

Media

All Videos

Insights

Interviews

Peer Exchange

Podcasts

Stakeholder Summit

Compendia

Conferences

Conference Coverage

Conference Listing

CME/CE

Resources

Authors

Biosimilar Resources

Interactive Tools

WHEN CHOICE ARRIVES: Competition & Consequences

Subscribe

E-News

Print Subscription

BIOSIMILAR APPROVALS

Videos

Here are the top 5 biosimilar articles for the week of September 18, 2023.

The Top 5 Biosimilar Articles for the Week of September 18

Articles

The European Commission approved the first aflibercept biosimilar, which will be used to treat patients with age-related macular degeneration and diabetic macular edema.

European Commission Approves First Aflibercept Biosimilar

Sarfaraz K. Niazi, PhD, is an adjunct professor of biopharmaceutical sciences at the University of Illinois and the University of Houston, and founder of biosimilars companies Karyo Biologics and Adello Biologics. He also founded the biosimilar advisory company PharmSci.

In the final part of a 3-part series, Sarfaraz K. Niazi, PhD, gives his take on the FDA's recent workshop dedicated to streamlining biosimilar development and his opinion on what the industry can learn from the webinar presenters.

Part 3: BioRationality—FDA Webinar on Biosimilars Efficacy Testing Marks Major Step Forward

A study evaluating the real-world impact of treating patients with inflammatory bowel disease (IBD) with an adalimumab biosimilar found that providing patient questionnaires early can be useful for identifying those at a higher risk of treatment discontinuation.

Patient Surveys Provide Insight Into Real-World Adalimumab Biosimilar Use in IBD

About

Contact

Advisory Board

Do Not Sell My Information

Terms & Conditions

Privacy Policy

Center for Biosimilars®

Facebook

Twitter

LinkedIn

Business Practice

Business

Development

Legal

Policy

Practice

Regulatory

1rem

Clinician and Managed Care Insights on Biosimilars for Inflammatory Diseases

Knowledge Gaps With Biosimilars

Differences Between Biosimilars and Generic Drugs

Approval Process for Biosimilars 

Naming of Biosimilars

Clinical Experience With Biosimilars

Use of Biosimilars in Inflammatory Diseases

Cost and Prescribing Considerations for Biosimilars

Variables Affecting Cost for Biosimilars

Formulary Considerations for Biosimilars

Challenges in Discussing Biosimilars With Patients

Clinician Awareness of Future Biosimilars

The Future of Biosimilars and Managing Inflammatory Diseases